287 related articles for article (PubMed ID: 28077047)
1. Extended infusion compared to standard infusion cefepime as empiric treatment of febrile neutropenia.
Wrenn RH; Cluck D; Kennedy L; Ohl C; Williamson JC
J Oncol Pharm Pract; 2018 Apr; 24(3):170-175. PubMed ID: 28077047
[TBL] [Abstract][Full Text] [Related]
2. Time to defervescence evaluation for extended- vs. standard-infusion cefepime in patients with acute leukemia and febrile neutropenia.
Crawford R; Perkins NB; Hobbs DA; Hobbs ALV
Pharmacotherapy; 2022 Oct; 42(10):798-805. PubMed ID: 36106434
[TBL] [Abstract][Full Text] [Related]
3. Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study.
Fehér C; Rovira M; Soriano A; Esteve J; Martínez JA; Marco F; Carreras E; Martínez C; Fernández-Avilés F; Suárez-Lledó M; Mensa J
J Antimicrob Chemother; 2014 Sep; 69(9):2556-62. PubMed ID: 24855125
[TBL] [Abstract][Full Text] [Related]
4. Impact of a cefepime shortage on dosing regimens and outcomes in hospitalized adults with febrile neutropenia.
Haiduc M; Patel M; Walsh TL; Moffa MA; Bremmer DN
J Oncol Pharm Pract; 2021 Mar; 27(2):297-304. PubMed ID: 32316878
[TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens.
Rhodes NJ; Grove ME; Kiel PJ; O'Donnell JN; Whited LK; Rose DT; Jones DR; Scheetz MH
Int J Antimicrob Agents; 2017 Sep; 50(3):482-486. PubMed ID: 28668694
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients: protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE).
Laporte-Amargos J; Gudiol C; Arnan M; Puerta-Alcalde P; Carmona-Torre F; Huguet M; Albasanz-Puig A; Parody R; Garcia-Vidal C; Del Pozo JL; Batlle M; Tebé C; Rigo-Bonnin R; Muñoz C; Padullés A; Tubau F; Videla S; Sureda A; Carratalà J
Trials; 2020 May; 21(1):412. PubMed ID: 32423462
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
8. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
Corapcioglu F; Sarper N; Zengin E
Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
[TBL] [Abstract][Full Text] [Related]
9. Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial.
Ram R; Halavy Y; Amit O; Paran Y; Katchman E; Yachini B; Kor S; Avivi I; Ben-Ami R
Clin Infect Dis; 2018 Sep; 67(8):1153-1160. PubMed ID: 29608680
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation.
Whited L; Grove M; Rose D; Rhodes NJ; Scheetz MH; O'Donnell JN; Neeb J; Thoele K; Jones DR; Lowe C; Moore D; Kiel PJ
Pharmacotherapy; 2016 Sep; 36(9):1003-10. PubMed ID: 27496678
[TBL] [Abstract][Full Text] [Related]
12. Smaller but more frequent dosing of cefepime in the treatment of febrile neutropenia.
Okubo L; Andrick B; Rampulla R; Leri F
J Oncol Pharm Pract; 2022 Jun; 28(4):898-903. PubMed ID: 35156879
[TBL] [Abstract][Full Text] [Related]
13. Assessment of an alternative meropenem dosing strategy compared with imipenem-cilastatin or traditional meropenem dosing after cefepime failure or intolerance in adults with neutropenic fever.
Arnold HM; McKinnon PS; Augustin KM; Hladnik LM; Casabar E; Reichley RM; Dubberke ER; Westervelt P; Ritchie DJ
Pharmacotherapy; 2009 Aug; 29(8):914-23. PubMed ID: 19637944
[TBL] [Abstract][Full Text] [Related]
14. Early discontinuation of empirical antibacterial therapy in febrile neutropenia: the ANTIBIOSTOP study.
Le Clech L; Talarmin JP; Couturier MA; Ianotto JC; Nicol C; Le Calloch R; Dos Santos S; Hutin P; Tandé D; Cogulet V; Berthou C; Guillerm G
Infect Dis (Lond); 2018 Jul; 50(7):539-549. PubMed ID: 29451055
[TBL] [Abstract][Full Text] [Related]
15. Cefepime vs. cefoperazone/sulbactam in combination with amikacin as empirical antibiotic therapy in febrile neutropenia.
Ponraj M; Dubashi B; Harish BH; Kayal S; Cyriac SL; Pattnaik J; Ranjith K; Pillai US; Jadhav N; Matta KK; Singh J; Jaffa E; Prakash B
Support Care Cancer; 2018 Nov; 26(11):3899-3908. PubMed ID: 29774477
[TBL] [Abstract][Full Text] [Related]
16. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
17. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
Corapçioglu F; Sarper N
Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
[TBL] [Abstract][Full Text] [Related]
18. A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Aamir M; Abrol P; Sharma D; Punia H
Trop Doct; 2016 Jul; 46(3):142-8. PubMed ID: 26612093
[TBL] [Abstract][Full Text] [Related]
19. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
20. Randomized study of cefepime versus ceftazidime plus amikacin in patients with solid tumors treated with high dose chemotherapy (HDC) and peripheral blood stem cell support (PBSCS) with febrile neutropenia.
Jimeno A; Arcediano A; Bazares S; Amador ML; González-Cortijo L; Ciruelos E; Robles L; Castellano D; Paz-Ares L; Lumbreras C; Hornedo J; Cortés-Funes H
Clin Transl Oncol; 2006 Dec; 8(12):889-95. PubMed ID: 17169762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
